Navigation Links
Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
Date:8/21/2008

6% to $26.0 million compared to $24.6 million in the prior year. Royalty income included $21.4 million in Angio-Seal(TM) royalties, up 3% from the prior year, and $4.4 million in royalties from Orthovita, up 19% from the prior year. Orthovita royalty growth was primarily due to the sales and marketing efforts of Orthovita, increase in its sales force and the full launch of the new VITOSS(R) Bioactive Foam product in the fourth fiscal quarter.

Earnings Per Share. Fiscal year 2008 adjusted diluted earnings per share* of $0.99, represents an increase of 87% compared to fiscal year 2007 adjusted diluted earnings per share of $0.53. Adjusted diluted earnings per share* for fiscal year 2008 excludes $11.4 million in net charges ($7.6 million in after-tax charges, or $0.61 per share tax effected), for the acceleration of stock awards, discontinuation of the Company's embolic protection platform, and sale of the Company's endovascular business. Adjusted diluted earnings per share* for fiscal year 2007 of $0.53 excludes $4.7 million in charges ($3.1 million in after-tax charges, or $0.25 per share tax effected) for the discontinuance of the Company's embolic protection platform. Including these items, reported diluted earnings per share for fiscal 2008 of $0.38, represents a 31% increase compared to fiscal year 2007 reported diluted earnings per share of $0.29.

* Diluted earnings per share excluding after-tax special charges are non-GAAP financial measures and should not be considered replacements for GAAP results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the accompanying table to this release.

In the fiscal year ended June 30, 2008, the total tax-effected impact on earnings per share of equity compensation expense was $0.28, of which $0.16 related to the acceleration of stock awards and $0.12 related to equity compensation expense prior to the acceleration, equity compensation
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
3. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
4. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
7. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
10. Arpida Reports Interim Results for Six Months to 30 June 2008
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Pharma, Inc.,(Nasdaq: IDMI ), a biotechnology company focused ... Timothy P. Walbert,president and chief executive officer, will present ... Diego on Thursday, November 1, 2007,at 2 p.m. PDT ... webcast of the presentation will be available live and ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) has announced the ... Financial and Accounting Officer.,Immunosyn,s former Chief Financial and ... as the company,s Chairman of the Board and,further ... believe that the platform technology and its resulting,biopharmaceutical ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
Cached Biology Technology:IDM Pharma to Present at BIOCOM Investor Conference 2IDM Pharma to Present at BIOCOM Investor Conference 3Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2
(Date:9/2/2014)... study published in the September 2014 issue of ... Child and Adolescent Psychiatry found that children ... an increased risk of developing diabetes if they ... the nationwide Danish registers, a group of researchers ... University Hospital, Denmark, studied 48,299children and adolescents with ...
(Date:9/2/2014)... N.C. -- When you accidentally touch a hot oven, ... the basic neural circuits involved in sensing and responding ... the molecular players. , Duke researchers have made a ... involved in pain in worms, and have built a ... 2 in Nature Communications , may help direct ...
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Nature's tiny engineers 2Nature's tiny engineers 3
... Jan. 7, 2014 DigitalPersona, Inc., a trusted ... that its TouchChip® TCS1 sensor is the only ... the Ministry of Public Security under general technical ... for the China Resident Identity Card.  Miaxis Biometrics ...
... FL (January 6, 2014) Of the 1.9 million species ... 1.3 million are invertebrates. They have served as model organisms ... of the important role of invertebrates in science including sea ... and Loligo for neurobiology research, the fruit fly ...
... 2014) Autism Speaks, the world,s leading autism science ... $2.7 million for the funding of 13 new research ... address Autism Speaks, Early Access to Care initiative to ... to high-quality early intervention for all children affected by ...
Cached Biology News:Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 2Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 3New organization brings together top researchers to sequence the genomes of invertebrates 2New organization brings together top researchers to sequence the genomes of invertebrates 3Autism Speaks awards nearly $2.7 million for new research projects 2Autism Speaks awards nearly $2.7 million for new research projects 3Autism Speaks awards nearly $2.7 million for new research projects 4
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: